Callodine Capital Management LP Makes New $1.11 Million Investment in Bruker Corporation $BRKR

Callodine Capital Management LP acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,000 shares of the medical research company’s stock, valued at approximately $1,105,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Spire Wealth Management increased its stake in shares of Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after buying an additional 665 shares during the period. Jones Financial Companies Lllp boosted its position in Bruker by 79.7% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after buying an additional 1,230 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in Bruker in the 2nd quarter worth $87,000. EverSource Wealth Advisors LLC grew its holdings in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after acquiring an additional 942 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Bruker by 727.9% in the third quarter. Nisa Investment Advisors LLC now owns 5,100 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 4,484 shares during the period. Institutional investors own 79.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on BRKR. Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Wednesday, December 10th. Bank of America boosted their price target on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 15th. UBS Group reaffirmed a “neutral” rating and set a $49.00 price target on shares of Bruker in a research report on Friday, February 13th. Wells Fargo & Company increased their price objective on Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, JPMorgan Chase & Co. lifted their price objective on Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $50.38.

Insider Activity at Bruker

In related news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at $7,064,365. The trade was a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.30% of the stock is currently owned by insiders.

Bruker Trading Down 3.7%

Shares of BRKR opened at $33.75 on Friday. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The firm’s 50-day moving average price is $43.50 and its 200-day moving average price is $41.01. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of -225.00, a PEG ratio of 2.10 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the company earned $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Monday, March 23rd. Bruker’s dividend payout ratio (DPR) is presently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.